Private Equity in Healthcare After Connecticut: Why the Life Sciences Industry Needs Stewardship Capital, Not Financial Engineering

The debate over private equity's role in healthcare has intensified in recent years. Critics point to hospital bankruptcies, physician burnout, rising costs, and examples where financial engineering appeared to take precedence over patient care.

Supporters argue that private capital has funded innovation, rescued struggling organizations, accelerated growth, and enabled healthcare organizations to navigate an increasingly complex operating environment. The truth lies somewhere in between.

Healthcare and particularly the pharmaceutical and life sciences sectors, requires enormous amounts of capital. Drug development is expensive, manufacturing infrastructure is complex, and emerging technologies such as cell and gene therapies, artificial intelligence, and precision medicine demand significant investment.

Private equity and other forms of private capital have played a critical role in funding these innovations. Yet recent developments suggest that healthcare transactions cannot be evaluated solely through the lens of traditional financial returns.

Connecticut's enactment of Senate Bill 196 in May 2026 represents a significant moment in this evolving conversation. While the legislation specifically addresses hospital ownership and sale-leaseback transactions, its implications extend far beyond hospitals. It raises a broader question that pharmaceutical executives, investors, and policymakers should consider:

Should healthcare organizations be managed like traditional financial assets, or should they be governed by a different set of principles that recognize their public health mission?

The answer may determine the future of healthcare investment.

Connecticut's Message to Investors

Connecticut's legislation emerged from concerns surrounding the financial struggles of hospitals owned by Prospect Medical Holdings. Policymakers became increasingly concerned that certain transactions generated substantial investor returns while leaving healthcare institutions burdened with long-term financial obligations.

The law does not prohibit private equity participation in healthcare. Instead, it establishes guardrails designed to ensure that financial transactions support rather than undermine healthcare delivery.

Hospitals must now demonstrate financial necessity before entering certain sale-leaseback arrangements. They must also certify that private equity investors do not influence clinical decision-making regarding admissions, discharges, diagnostic testing, and patient care policies.

The significance of the legislation extends beyond its specific provisions. Connecticut is effectively signaling that healthcare organizations occupy a unique position in society.

Unlike traditional businesses, they serve critical public functions that affect patient outcomes, community well-being, and economic productivity.

For leaders in the pharma space, this development should not be viewed simply as a hospital policy issue. It reflects a broader shift in how regulators, policymakers, and the public are beginning to think about healthcare ownership and governance.

Why Healthcare is Different

Traditional private-equity investments are typically evaluated using familiar metrics: revenue growth, EBITDA expansion, return on investment, leverage optimization, and exit valuation. These metrics remain important; however, healthcare organizations create value in ways that extend beyond financial performance.

A pharmaceutical company developing a breakthrough therapy creates value not only for shareholders but also for patients, caregivers, healthcare systems, and society. A contract development and manufacturing organization (CDMO) contributes not only to profits but also to supply chain resilience. A specialty pharmacy influences not only financial outcomes but also patient adherence and access.

The life sciences sector operates at the intersection of commerce and public health, which creates responsibilities that do not exist in most industries. A consumer products company can discontinue a product line with relatively limited societal consequences.

A pharmaceutical company discontinuing production of a critical medicine may create shortages that affect thousands of patients. Similarly, decisions regarding manufacturing capacity, supply chain redundancy, quality systems, and workforce investment often have implications that extend far beyond quarterly earnings reports.

The challenge for investors is determining how to capture these broader forms of value.

The Case for Private Equity in Life Sciences

Despite growing criticism, private equity remains an essential source of capital for healthcare innovation. Over the past two decades, private investment has fueled growth across multiple sectors of healthcare and life sciences, including specialty pharmaceuticals, healthcare technology, diagnostics, contract manufacturing, outpatient care, and digital health.

Many promising healthcare innovations would never reach patients without private capital. The emerging cell and gene therapy sector provides a powerful example.

Developing a single gene therapy may require hundreds of millions of dollars in investment before generating meaningful revenue. Manufacturing infrastructure, regulatory compliance, cold-chain logistics, and commercialization capabilities all require substantial capital commitments.

Private equity and growth investors help bridge these gaps. Similarly, pharmaceutical supply chains face growing demands for resilience, geographic diversification, and advanced manufacturing technologies.

Achieving these objectives requires investments that many organizations cannot fund independently. The issue, therefore, is not whether private capital should participate in healthcare.

The issue is how capital should be deployed.

When Financial Engineering Becomes a Problem

Many concerns regarding private equity stem not from ownership itself but from transaction structures that prioritize short-term extraction of value over long-term value creation. Sale-leaseback arrangements represent one example.

While such transactions may improve short-term liquidity, they can also create long-term financial obligations that reduce organizational flexibility and resilience. The pharmaceutical industry has experienced similar tensions.

Over the past decade, many companies have optimized supply chains for efficiency, reduced inventory buffers, consolidated manufacturing networks, and concentrated production in lower-cost regions. These decisions often improved short-term financial performance.

However, the COVID-19 pandemic exposed the vulnerabilities created by excessive optimization. Supply disruptions, shortages of active pharmaceutical ingredients, and manufacturing bottlenecks demonstrated that resilience carries value even when it reduces short-term efficiency.

The lesson is clear: Financial engineering can improve quarterly results, but healthcare organizations must also consider their ability to fulfill their mission over the long term.

Introducing Healthcare Stewardship Capital

The Connecticut legislation points toward a broader concept that may shape the future of healthcare investment: Healthcare Stewardship Capital. Traditional financial capital focuses primarily on economic returns.

Healthcare Stewardship Capital recognizes that healthcare organizations create multiple forms of value simultaneously:

• financial value
• clinical value
• patient value
• community value
• public health value
• institutional value

Under this framework, investors seek attractive returns while simultaneously strengthening the long-term capabilities of the organizations they support. The objective is not to sacrifice profitability, but rather to redefine value creation.

A pharmaceutical manufacturer that invests in redundant production capacity may incur higher short-term costs but create greater long-term value through improved reliability and supply continuity. A healthcare technology company that prioritizes patient privacy and trust may sacrifice some short-term growth opportunities while strengthening its long-term competitive position.

A life sciences investor that supports workforce development, quality systems, and operational resilience may ultimately create more sustainable value than one focused exclusively on financial optimization.

A New Scorecard for Healthcare Investments

The life sciences industry needs a broader framework for evaluating investment decisions. In addition to traditional financial metrics, healthcare organizations should consider four dimensions of performance.

• Financial Sustainability. Can the organization continue investing in innovation, growth, and patient services over the long term?
• Patient Impact. How does the investment affect patient outcomes, access, adherence, and quality of care?
• Trust and Reputation. Does the decision strengthen confidence among patients, providers, regulators, employees, and investors?
• Resilience. Does the organization become better prepared to withstand future disruptions, shortages, regulatory changes, and market volatility?

Organizations that consistently perform well across all four dimensions are likely to create more durable value than those focused exclusively on financial returns.

The Future of Healthcare Investment

Connecticut's legislation may represent the beginning of a broader trend. Policymakers across multiple states are increasingly scrutinizing healthcare transactions through the lens of patient welfare, community impact, and long-term sustainability.

The implications are significant, as investors, regulators, healthcare providers, and patients are increasingly asking the same question: Does this transaction create lasting value for the healthcare system, or does it simply transfer value from one stakeholder group to another?

The organizations best positioned for future success will be those that recognize healthcare's unique role in society. They will understand that trust, resilience, quality, and patient outcomes are not constraints on value creation.

They are sources of value creation.

Conclusion

Healthcare does not need less capital, it needs better-aligned capital. Private equity, venture capital, and institutional investors will continue to play critical roles in funding innovation across the pharmaceutical and healthcare sectors.

However, Connecticut's recent legislation highlights a growing recognition that healthcare transactions must be evaluated differently from traditional financial transactions. The future belongs not to organizations that maximize short-term returns at the expense of long-term capability, but to those that recognize healthcare's dual mission as both an economic enterprise and a public trust.

The next evolution of healthcare finance may therefore be defined by a simple principle: Financial returns matter, innovation matters, and patient welfare matters. The most successful healthcare investments will be those that recognize these objectives are not competing priorities, they are mutually reinforcing.

That is the promise of Healthcare Stewardship Capital.

About the Author

Thani Jambulingam, PhD, is a professor in food, pharma and healthcare at Erivan K. Haub School of Business, Saint Joseph’s University, Philadelphia. He is a pharma and healthcare strategist and his work focuses on AI-enabled decision frameworks, emerging technologies, and commercial strategy. He can reached at tjambuli@sju.edu.